Targeting estrogen receptor signaling for treating heart failure
Related Experiment Video
Updated: Jul 15, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Chenyue Qian1, Jingjin Liu2,3,4,5,6, Huadong Liu7,8,9,10,11
1The Second Clinical Medical College, Jinan University, Shenzhen, 518020, Guangdong, China.
Abstract:
Heart failure (HF) is a significant public health problem worldwide. It has long been noted that premenopausal women, compared to postmenopausal women and men, have lower rates for developing this disease, as well as subsequent morbidity and mortality. This difference has been attributed to estrogen playing a cardioprotective role in these women, though exactly how it does so remains unclear. In this review, we examine the presence of estrogen receptors within the cardiovascular system, as well as the role they play behind the cardioprotective effect attributed to estrogen. Furthermore, we highlight the underlying mechanisms behind their alleviation of HF, as well as possible treatment approaches, such as hormone replacement therapy and exercise regimens, to manipulate these mechanisms in treating and preventing HF.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers

